Table 3.
Comparison of end‐organ function parameters obtained prior to VA‐ECMO weaning between the 30 day survivor and non‐survivor groups
| Overall (n = 50) | 30 day survivors (n = 24) | Non‐survivors (n = 26) | P value | |
|---|---|---|---|---|
| SOFA score | 11.0 (8.0–13.0) | 9.0 (7.0–12.0) | 11.0 (9.5–13.5) | 0.091 |
| ABG analysis | ||||
| pH | 7.47 (7.42–7.50) | 7.46 (7.43–7.50) | 7.47 (7.37–7.51) | 0.79 |
| Bicarbonate (mmol/L) | 23.9 (22.9–26.3) | 23.7 (22.0–25.9) | 24.6 (23.0–26.9) | 0.51 |
| Lactate (mg/dL) | 11.7 (9.6–17.6) | 11.2 (9.0–16.0) | 14.3 (10.1–21.7) | 0.073 |
| Laboratory data | ||||
| Total bilirubin (mg/dL) | 1.8 (1.0–4.4) | 1.3 (0.8–3.0) | 2.2 (1.2–5.1) | 0.13 |
| Aspartate aminotransferase (IU/L) | 107 (70–246) | 107 (59–192) | 106 (72–267) | 0.57 |
| Alanine aminotransferase (IU/L) | 50 (23–138) | 41 (21–250) | 56 (27–110) | 0.57 |
| Lactate dehydrogenase (IU/L) | 944 (576–1338) | 687 (464–1023) | 1047 (682–1562) | 0.020 |
| Creatine phosphokinase (IU/L) | 735 (398–2108) | 736 (362–2219) | 728 (359–2389) | 0.83 |
| Blood urine nitrogen (mg/dL) | 34 (21–46) | 31 (19–49) | 34 (25–45) | 0.70 |
| Serum creatinine (mg/dL) | 1.38 (0.82–2.28) | 0.90 (0.76–2.82) | 1.49 (0.88–2.19) | 0.78 |
| White blood cell count (/μL) | 9000 (6500–12 650) | 7000 (6075–11 950) | 11 000 (7125–13 700) | 0.079 |
| C‐reactive protein (mg/dL) | 11.2 (6.8–16.0) | 9.7 (6.3–14.4) | 12.0 (7.2–20.8) | 0.24 |
ABG, arterial blood gas; SOFA, sequential organ failure assessment; VA‐ECMO, veno‐arterial extracorporeal membrane oxygenation.